Cyclerion Therapeutics
CYCN
19 hedge funds and large institutions have $376K invested in Cyclerion Therapeutics in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
12% more funds holding
Funds holding: 17 → 19 (+2)
0.21% less ownership
Funds ownership: 7.76% → 7.55% (-0.21%)
37% less capital invested
Capital invested by funds: $595K → $376K (-$219K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$50.5K |
| 2 |
Two Sigma Investments
New York
|
+$50.5K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$17.9K |
| 4 |
Citigroup
New York
|
+$14.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$100K |
| 2 |
Morgan Stanley
New York
|
-$1.16K |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$985 |
| 4 |
Barclays
London,
United Kingdom
|
-$12 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$11 |
CYCN Hedge Fund Activity: Q4 2025 in Review
19 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q4 2025, worth a combined $376K — down 37% from $595K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CYCN positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $50.5K. The largest seller was DRW Securities, exiting entirely with an estimated $100K sold.
- 19 institutional investors held Cyclerion Therapeutics (CYCN) as of Q4 2025, up from 17 in Q3 2025.
- Funds reported $376K of Cyclerion Therapeutics stock for Q4 2025, down 37% quarter-over-quarter.
- 4 funds opened new Cyclerion Therapeutics positions in Q4 2025 and 2 closed out, a net change of +2 holders.
- The largest Cyclerion Therapeutics buyer in Q4 2025 was Two Sigma Advisers, an estimated $50.5K added.
- The largest Cyclerion Therapeutics seller in Q4 2025 was DRW Securities, an estimated $100K sold.
Based on aggregated 13F filings for Q4 2025.